pharmaphorum
AUGUST 23, 2021
The COVID-19 pandemic accelerated the development of mRNA-based vaccines, and its influence has now extended to DNA-based shots as well, with Zydus Cadila’s ZyCoV-D getting emergency use authorisation in India. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.
STAT News
APRIL 17, 2023
Genetic engineering has the potential to transform how we raise animals for meat and other products, making food safer, improving animal health and welfare, and shrinking animal agriculture’s environmental footprint. Salmon that reach market size in 18 months instead of 30.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
FEBRUARY 15, 2023
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Regeneron has a market cap of $78.64
pharmaphorum
MAY 7, 2021
Founded by Nobel prize winner Emmanuelle Charpentier, CRISPR Therapeutics has been at the forefront of the gene editing technology and has refined it to the point where it can be used to accurately edit DNA to correct genetic conditions or modify cells to fight disease.
Drug Discovery World
MAY 7, 2024
RA: In recent years, what improvements have we seen to cell-line engineering for antibodies? DC: Antibodies have and remain a large product class within the biopharmaceutical market. AEX chromatography has primarily been used in the polishing AEX step for the removal of impurities, such as DNA, HCP, etc.,
Drug Discovery World
FEBRUARY 14, 2024
While a typical chemisty, manufacturing and controls (CMC) timeline from DNA to Investigational New Drug (IND) application in 2015 would have been approximately 24 months, by 2023 the same pathway was expected to take only 10 months. Consistent and reliable supply chains have also become a key consideration.
Drug Discovery World
JULY 5, 2023
Global Cancer Segment Market Manager at Agilent Technologies, recently sat down with DDW Editor Reece Armstrong to tell us about the developments in the ‘golden age’ of cancer research. As part of his graduate work he invented the gel-shift or EMSA assay for the study of protein-DNA interactions. Mark Garner, PhD.,
Expert insights. Personalized for you.
98 
Let's personalize your content